首页> 美国卫生研究院文献>Psychopharmacology Bulletin >Paroxetine—The Antidepressant from Hell? Probably Not But Caution Required
【2h】

Paroxetine—The Antidepressant from Hell? Probably Not But Caution Required

机译:帕罗西汀-来自地狱的抗抑郁药?可能不是但是需要小心

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various anxiety disorders, it quickly gained a sizable share of the antidepressant prescription market. By the late 1990s, paroxetine frequently was being associated with serious drug interactions and medication side effects. Most significantly, in a major Canadian epidemiological study examining the relationship between antidepressants and diseases, paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period. Though re-analyses of this investigation discounted the magnitude of these findings, other studies have associated paroxetine with numerous side effects and adverse events not reported in clinical trials. Among these are effects on male fertility, birth defects, gestational hypertension, prolonged QT interval in infants, hyperprolactinemia, cognitive impairment in the elderly, autism, sexual side effects, weight gain, and suicidality, aggression, and akathisia in children and adolescents. Paroxetine has the highest inhibitory constant for the P450 2D6 isoenzyme of all antidepressants (Ki = 0.065–4.65 micromoles). This high affinity explains its high inhibitory interaction profile with substrates for 2D6. Paroxetine’s potent 2D6 inhibition also implies that significant inhibition of the metabolism of 2D6 carcinogen substrates occurs which implies an increased probability of oncogenesis. Through 2D6 inhibition, tamoxifen metabolism is inhibited, which has been found to increase the risk of dying from breast cancer over a five-year period in women on both medications. Paroxetine also is a potent inhibitor of 3A4 with multiple 3A4 substrate interactions. Paroxetine has the highest known affinity for the serotonin transporter (0.13 nanomoles) of any currently used antidepressant. These characteristics and their potential negative consequences along with other adverse effects are considered and weighed against paroxetine’s efficacious antidepressant and anxiolytic effects.
机译:帕罗西汀(Paoxetine)也以商品名Aropax,Paxil,Pexeva,Seroxat,Sereupin和Brisdelle着称,于1992年在美国首次上市。对重度抑郁症和各种焦虑症有效,它很快在抗抑郁药处方药市场上占有相当大的份额。到1990年代后期,帕罗西汀经常与严重的药物相互作用和药物副作用相关。最重要的是,在一项主要的加拿大流行病学研究中,研究了抗抑郁药与疾病之间的关系,在服用了四年的妇女中,帕罗西汀与乳腺癌发生率增加620%有关。尽管对本研究的重新分析不重视这些发现,但其他研究已将帕罗西汀与许多副作用和不良事件相关联,而这些副作用和不良事件在临床试验中未见报道。其中包括对男性生育力,出生缺陷,妊娠高血压,婴儿延长QT间隔,高泌乳素血症,老年人的认知障碍,自闭症,性副作用,体重增加和自杀倾向,攻击性和儿童和青少年静坐症的影响。帕罗西汀对所有抗抑郁药的P450 2D6同工酶具有最高的抑制常数(Ki = 0.065–4.65微摩尔)。这种高亲和力说明了它与2D6底物的高抑制性相互作用。帕罗西汀对2D6的有效抑制作用还意味着对2D6致癌物底物代谢的显着抑制,这意味着致癌的可能性增加。通过2D6抑制作用,他莫昔芬的代谢受到抑制,发现这两种药物的妇女在5年内会增加死于乳腺癌的风险。帕罗西汀还是具有多种3A4底物相互作用的有效3A4抑制剂。在任何目前使用的抗抑郁药中,帕罗西汀对5-羟色胺转运蛋白的亲和力最高(0.13纳摩尔)。这些特征及其潜在的负面影响以及其他不利影响已与帕罗西汀的有效抗抑郁药和抗焦虑药进行了权衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号